Page 4; BTA said: Quote: - GSK restricted Relenza to its proprietary Diskhaler system, and did not adequately pursue alternative or improved inhalation system.
- GSK withdrew support for crucial post-approval clinical studies designed to expand the product’s use and market acceptance.
Any objective reader would know who is the culprit from the above BTA document.
This is fast becoming a FDA bashing site so as to make GSK looks good even to the extend of claiming FDA refused Relenza approval and delayed the approval to one year after Tamiflu.
BTA Price at posting:
$2.95 Sentiment: None Disclosure: Not Held